Virtual Reality Exhibit Simulates Cancer Fatigue

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 7
Volume 7
Issue 7

LOS ANGELES--Visitors to the Exhibitor’s Hall at this year’s ASCO meeting had the opportunity to walk in the shoes of a patient with cancer-related fatigue at Ortho-Biotech’s In My Steps virtual reality experience, developed in cooperation with cancer patients and the Fatigue Coalition.

LOS ANGELES--Visitors to the Exhibitor’s Hall at this year’s ASCO meeting had the opportunity to walk in the shoes of a patient with cancer-related fatigue at Ortho-Biotech’s In My Steps virtual reality experience, developed in cooperation with cancer patients and the Fatigue Coalition.

For this virtual journey, you sit in a special chair outfitted with pedals. A technician fits you with a virtual reality helmet (see Figure) that places you in the simulated house, and in the shoes, of a fatigued cancer patient. Using the pedals to "walk" and a hand-guided pointer to direct your movements, you guide the patient through simple tasks made challenging by the resistant pedals that slow your steps. Just making a cup of tea becomes maddeningly difficult as the kettle whistles, the doorbell rings, and an impatient delivery man leaves before you can reach the door. The experience, of course, cannot simulate the debilitating fatigue that many cancer patients describe. In one survey, 29% said they had difficulty just getting out of bed, and 24% were too tired to eat. It does, however, reveal the frustrations such patients feel.

In My Steps is traveling to cancer centers as part of 1-day fatigue awareness workshops for physicians and nurses. To schedule an event, call 1-800-776-2748.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content